Raymond James analyst Ryan Deschner raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $77 from $73 and keeps a Strong Buy rating on the shares. The price target increase is driven by bile acid portfolio and Livmarli net sales in addition to raised guidance for fiscal 2025, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Buy Rating on Mirum Pharmaceuticals: Promising Phase 2b VANTAGE Study Results and Strong Market Potential
- Mirum’s volixibat shows ‘best-in-class potential,’ says Citi
- Mirum Pharmaceuticals price target raised to $76 from $74 at Citizens JMP
- Mirum Pharmaceuticals Reports Robust Q1 2025 Growth
- Mirum Pharmaceuticals: Strong Financial Performance and Promising Prospects Justify Buy Rating